These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11367198)

  • 1. AIDS practice issues today: interview with Paul Bellman, M.D. Interview by John S. James.
    Bellman P
    AIDS Treat News; 2000 Apr; (No 340):1-6. PubMed ID: 11367198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term strategies: should some patients wait to start protease inhibitors? Interview with Keith Henry, M.D. Interview by John S. James.
    Henry K
    AIDS Treat News; 1997 Oct; (No 281):1, 3-6. PubMed ID: 11364791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New antiretroviral tactics: transitions or mere trends? An interview with Joep Lange,MD,PhD. Interview by Mark Mascolini.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1999 Jul; 5(7):25-9. PubMed ID: 11367133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How far can you knock down HIV? An interview with David D. Ho, MD. Interview by Mark Mascolini.
    Ho DD
    J Int Assoc Physicians AIDS Care; 1997 Jun; 3(6):40-4. PubMed ID: 11364429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence and double therapies: an interview with Charles Farthing, M.D. Interview by Marcelo Marer.
    Farthing C
    Body Posit; 1998; 11(4-5):28-33. PubMed ID: 11365254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retroviruses Conference clinical news; interview with Cal Cohen, M.D. Interview by John S. James.
    Cohen C
    AIDS Treat News; 2003 Mar; (389):2-6. PubMed ID: 12712936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity of antiretroviral therapy and implications for drug development.
    Carr A
    Nat Rev Drug Discov; 2003 Aug; 2(8):624-34. PubMed ID: 12904812
    [No Abstract]   [Full Text] [Related]  

  • 8. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
    Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
    Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protease inhibitors and nucleosides: how many? when? An interview with Stefano Vella, MD. Interview by Mark Mascolini.
    Vella S
    J Int Assoc Physicians AIDS Care; 1995 Dec; 1(11):12-8. PubMed ID: 11363089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV medicine after Barcelona conference: interview with Howard Grossman, M.D. Interview by John S. James.
    Grossman H
    AIDS Treat News; 2002 Sep; (383):2-7. PubMed ID: 12765126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV research overview: interview with David Ho, M.D. Interview by John S. James.
    Ho D
    AIDS Treat News; 1997 Nov; (No 282):1-6. PubMed ID: 11364903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Increased girth, thin arms. Unusual changes in HIV therapy].
    MMW Fortschr Med; 1999 Sep; 141(36):62-3. PubMed ID: 10904607
    [No Abstract]   [Full Text] [Related]  

  • 16. Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response.
    Nieuwkerk P; Gisolf E; Sprangers M; Danner S;
    Antivir Ther; 2001 Jun; 6(2):97-103. PubMed ID: 11491422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
    Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activism today: the Coalition for Salvage Therapy. Interview with Linda Grinberg. Interview by John S. James.
    Grinberg L
    AIDS Treat News; 1999 Nov; (No 330):2-4. PubMed ID: 11367171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-drug or six-drug antiretroviral therapy--conversation with Steven Scheibel, M.D. Interview by John S. James.
    Scheibel S
    AIDS Treat News; 1996 Aug; (No 253):1-2. PubMed ID: 11363765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
    Spire B; Marcellin F; Cohen-Codar I; Flandre P; Boue F; Dellamonica P; Raffi F; Norton M; Van Philippe N; Delfraissy JF
    Antivir Ther; 2008; 13(4):591-9. PubMed ID: 18672538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.